SRPT - Sarepta Therapeutics, Inc. Stock Price and Quote

SRPT [NASD]

Index	-	P/E	-	EPS (ttm)	-8.03	Insider Own	0.20%	Shs Outstand	87.84M	Perf Week	5.96%
Market Cap	11.62B	Forward P/E	29.18	EPS next Y	4.59	Insider Trans	-0.49%	Shs Float	83.68M	Perf Month	12.02%
Income	-703.50M	PEG	-	EPS next Q	-1.44	Inst Own	89.10%	Short Float / Ratio	6.50% / 3.85	Perf Quarter	8.04%
Sales	933.00M	P/S	12.45	EPS this Y	-55.90%	Inst Trans	6.96%	Short Interest	5.44M	Perf Half Y	26.29%
Book/sh	4.38	P/B	30.57	EPS next Y	192.00%	ROA	-22.80%	Target Price	169.53	Perf Year	79.84%
Cash/sh	22.93	P/C	5.84	EPS next 5Y	-	ROE	-117.30%	52W Range	61.28 - 159.84	Perf YTD	5.58%
Dividend	-	P/FCF	-	EPS past 5Y	-56.30%	ROI	-35.10%	52W High	-14.41%	Beta	1.00
Dividend %	-	Quick Ratio	3.80	Sales past 5Y	43.30%	Gross Margin	85.00%	52W Low	123.25%	ATR	6.37
Employees	1162	Current Ratio	4.10	Sales Q/Q	28.20%	Oper. Margin	-71.20%	RSI (14)	52.17	Volatility	2.91% 4.27%
Optionable	Yes	Debt/Eq	4.01	EPS Q/Q	12.40%	Profit Margin	-75.40%	Rel Volume	0.59	Prev Close	133.90
Shortable	Yes	LT Debt/Eq	4.01	Earnings	Feb 28 AMC	Payout	-	Avg Volume	1.41M	Price	136.81
Recom	1.80	SMA20	-3.38%	SMA50	4.70%	SMA200	22.34%	Volume	356,167	Change	2.17%

Mar-01-23

Upgrade

Morgan Stanley

Equal-Weight → Overweight

$141 → $187

Dec-22-22

Reiterated

BTIG Research

Buy

$125 → $160

Dec-16-22

Upgrade

UBS

Neutral → Buy

$100 → $158

Apr-04-22

Resumed

Cantor Fitzgerald

Overweight

$140

Jan-05-22

Reiterated

Needham

Buy

$157 → $150

Dec-09-21

Upgrade

Oppenheimer

Perform → Outperform

$125

Nov-05-21

Upgrade

JP Morgan

Neutral → Overweight

$130

Sep-15-21

Upgrade

Guggenheim

Neutral → Buy

Aug-05-21

Upgrade

JP Morgan

Underweight → Neutral

$92 → $87

Jun-15-21

Initiated

BTIG Research

Buy

$110

Show Previous Ratings

Mar-29-23 09:26AM	Sarepta Therapeutics' (NASDAQ:SRPT) growing losses don't faze investors as the stock advances 3.7% this past week Simply Wall St.
Mar-25-23 06:00AM	3 Up-and-Coming Growth Stocks to Buy Right Now Motley Fool
Mar-21-23 04:16PM	Accelerated Approval For Gene Therapies - US Health Regulator Looks To Improve Process Benzinga
03:02AM	Sarepta Therapeutics (SRPT) Soars 7.1%: Is Further Upside Left in the Stock? Zacks
Mar-17-23 04:05PM	Sarepta Crashes On An Unexpected Roadblock For Its Gene Therapy Investor's Business Daily -18.03%
02:54PM	Loading…
02:54PM	Sarepta (SRPT) Stock Down, FDA to Hold Panel Meet for SRP-9001 Zacks
02:00PM	Sarepta Plunges As FDA Takes Surprise Turn; AdComm Meeting Set For Duchenne Gene Therapy Benzinga
01:20PM	Why Weakness in Sarepta Therapeutics Is Likely to Continue TheStreet.com
11:39AM	First Republic Banks stock plunge continues despite $30 billion bank boost, FedExs stock jumps after blowout earnings report MarketWatch
11:22AM	Sarepta Therapeutics Plunges on Drug Approval Doubts. Buy the Stock, Analysts Say. Barrons.com
09:50AM	The 2 Stocks to Watch on a Nail-Biter Friday Motley Fool
08:17AM	Sarepta slides as FDA about-turn on panel clouds gene therapy approval path Reuters
Mar-16-23 06:16PM	Sarepta Therapeutics plummets 20% after FDA contradicts company and requires advisory meeting MarketWatch
04:05PM	Sarepta Therapeutics Announces Advisory Committee Meeting will be Held for SRP-9001 Business Wire
Mar-09-23 08:30AM	2 Biotech Stocks You Can Buy and Hold for the Next Decade Motley Fool
09:28PM	Loading…
Mar-02-23 09:28PM	Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q4 2022 Earnings Call Transcript Insider Monkey +5.06%
03:26PM	Why Sarepta Therapeutics' Shares Rose 23.4% This Week Motley Fool
05:23AM	Sarepta Therapeutics Full Year 2022 Earnings: EPS Misses Expectations Simply Wall St.
Mar-01-23 04:08PM	Sarepta Rockets And Breaks Out As FDA Smooths The Path For Its Gene Therapy Investor's Business Daily +19.24%
02:45PM	Sareptas stock still up after Tuesdays announcement that its Duchenne drug candidate wont require a FDA AdCom meeting MarketWatch
11:02AM	Sarepta (SRPT) Q4 Earnings & Sales Beat Estimates, Stock Up Zacks
09:09AM	Investors Just Hit the Jackpot on These 2 Nasdaq Biotech Stocks Motley Fool
Feb-28-23 09:30PM	Sarepta Therapeutics (SRPT) Q4 2022 Earnings Call Transcript Motley Fool
07:35PM	Sarepta Therapeutics (SRPT) Reports Q4 Loss, Tops Revenue Estimates Zacks
06:44PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
04:45PM	Sarepta stock surges more than 10% as results top expectations, drug given priority review MarketWatch
04:05PM	Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments Business Wire
09:00AM	Sarepta Therapeutics Announces Call for Applications for the 6th Annual Route 79, The Duchenne Scholarship Program Business Wire
Feb-27-23 09:31AM	Drug, Biotech Stocks' Q4 Earnings on Feb 28: NVAX, IOVA & More Zacks
Feb-22-23 10:00AM	Intercept Pharmaceuticals (ICPT) May Report Negative Earnings: Know the Trend Ahead of Q4 Release Zacks
08:30AM	Loading…
Feb-21-23 08:30AM	Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2022 Financial Results Business Wire
Feb-17-23 08:30AM	Sarepta Therapeutics Announces Initiation of VOYAGENE, a Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4 Business Wire
Feb-06-23 05:19AM	A Sarepta Therapeutics, Inc. (NASDAQ:SRPT) insider increased their holdings by 47% last year Simply Wall St.
Jan-31-23 06:20PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
12:12PM	MD gene therapy invented at Nationwide Children's could hit $4B annual sales if approved American City Business Journals
Jan-18-23 03:44PM	7 Biotech Stocks That Will Make You Rich in 10 Years InvestorPlace
Jan-09-23 01:28PM	Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2022 Net Product Revenues GlobeNewswire
Jan-08-23 08:39AM	Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Is Expected To Breakeven In The Near Future Simply Wall St.
Jan-06-23 08:45AM	2 Under-the-Radar Biotech Stocks to Buy in 2023 Motley Fool
Jan-05-23 08:30AM	Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate Business Wire
Jan-03-23 08:30AM	Sarepta Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-30-22 05:58PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Dec-09-22 09:53AM	2 Top Healthcare Stocks to Buy for the Long Haul Motley Fool
Dec-02-22 11:31AM	Sarepta Therapeutics (SRPT) Up 17.1% Since Last Earnings Report: Can It Continue? Zacks
Nov-30-22 06:00PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Nov-29-22 12:07PM	Sarepta's (SRPT) DMD Gene Therapy BLA Gets FDA Priority Review Zacks
Nov-28-22 04:12PM	Sarepta Surges As It Nears The Finish Line With A Muscular Dystrophy Gene Therapy Investor's Business Daily
08:50AM	Sarepta expected to get FDA decision on Duchenne treatment by May 29 MarketWatch
07:00AM	Sarepta Therapeutics Announces That U.S. FDA has Accepted for Filing and Granted Priority Review for the Biologics License Application for SRP-9001, Sareptas Gene Therapy for the Treatment of Ambulant Individuals with Duchenne Muscular Dystrophy GlobeNewswire
Nov-23-22 08:30AM	Sarepta Therapeutics to Present at the Evercore ISI HealthCONx Conference GlobeNewswire
Nov-03-22 01:25PM	Sarepta (SRPT) Q3 Loss Wider-Than-Expected, Sales Lag Estimates Zacks -7.41%
08:12AM	Dow Jones Futures Fall: Market Rally Reeling As Fed's Powell Signals Higher Peak Rate Investor's Business Daily
06:07AM	Stock Market Rally Tumbles As Fed's Powell Hints At Slower Hikes, But Higher Peak Rate Investor's Business Daily
02:00AM	Sarepta Therapeutics (SRPT) Q3 2022 Earnings Call Transcript Motley Fool
Nov-02-22 06:25PM	Sarepta Therapeutics (SRPT) Reports Q3 Loss, Lags Revenue Estimates Zacks
04:05PM	Sarepta Therapeutics Announces Third Quarter 2022 Financial Results and Recent Corporate Developments GlobeNewswire
Oct-31-22 06:00PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
08:49AM	Top 10 Stock Picks of Eli Casdins Casdin Capital Insider Monkey
Oct-29-22 06:00AM	3 Unstoppable Stocks That Could Double in 5 Years Motley Fool
Oct-27-22 10:02AM	Fulcrum Therapeutics, Inc. (FULC) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
Oct-26-22 10:01AM	Earnings Preview: Sarepta Therapeutics (SRPT) Q3 Earnings Expected to Decline Zacks
08:30AM	Sarepta Therapeutics to Announce Third Quarter 2022 Financial Results GlobeNewswire
Oct-24-22 10:13AM	10 Best Pharma Stocks To Buy Now Insider Monkey
Oct-19-22 09:53AM	2 Under-the-Radar Biotech Stocks to Buy in 2022 Motley Fool
Oct-17-22 04:08PM	Why IBD Stock Of The Day Sarepta Just Snagged A Price Target Hike Over Pfizer Investor's Business Daily
Oct-07-22 08:30AM	Sarepta Therapeutics Presents New Data from its Gene Therapy and RNA Platforms at World Muscle Society 2022 GlobeNewswire
Oct-06-22 08:45AM	The Zacks Analyst Blog Highlights CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics Zacks
Sep-30-22 06:15PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
02:26PM	Best Stocks In The IBD 50 Can Be Found By Using This Simple Tool Investor's Business Daily
01:27PM	Nationwide Children's-invented gene therapy up for FDA approval American City Business Journals
01:20PM	Sarepta (SRPT) Seeks FDA Nod for DMD Gene Therapy Candidate Zacks
Sep-29-22 08:30AM	Sarepta Therapeutics Submits Biologics License Application for SRP-9001 for the Treatment of Ambulant Patients with Duchenne Muscular Dystrophy GlobeNewswire
Sep-28-22 01:59PM	PepGen's Duchenne Candidate Has Potential For Greater Exon Skipping Capabilities At Lower Doses Versus Sarepta's Candidate, Says Analyst Benzinga
Sep-14-22 07:10AM	Sarepta prices almost $1 billion convertible bond offering MarketWatch
07:00AM	Sarepta Therapeutics Prices $1.0 Billion of Convertible Senior Notes Due 2027 GlobeNewswire
Sep-12-22 04:41PM	Sarepta Therapeutics Announces Proposed Offering of $1.0 Billion of Convertible Senior Notes Due 2027 GlobeNewswire
11:20AM	Sarepta (SRPT) Stock Up 76.8% in Three Months: Here's Why Zacks
Sep-11-22 09:26AM	Investors bid Sarepta Therapeutics (NASDAQ:SRPT) up US$793m despite increasing losses YoY, taking five-year CAGR to 21% Simply Wall St.
Sep-08-22 01:31PM	A Biotech's Stock Just Hit Year High. This Analyst Expects It To Jump Another 16% Benzinga +5.62%
Sep-07-22 10:08AM	Clinical Hold on Sarepta's (SRPT) DMD Candidate Lifted by FDA Zacks
08:30AM	Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2022-2023 Academic Year GlobeNewswire
Sep-06-22 09:27AM	FDA Lifts Clinical Hold On Sarepta's Dose-Expansion Part Of Duchenne Trial Benzinga
08:45AM	Sarepta Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference GlobeNewswire
08:30AM	Sarepta Therapeutics Announces That FDA has Lifted its Clinical Hold on SRP-5051 for the Treatment of Duchenne Muscular Dystrophy GlobeNewswire
Sep-02-22 11:31AM	Mirati (MRTX) Up 5.3% Since Last Earnings Report: Can It Continue? Zacks
Sep-01-22 11:31AM	Why Is Sarepta Therapeutics (SRPT) Up 13.8% Since Last Earnings Report? Zacks
Aug-31-22 05:59PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Aug-30-22 01:47PM	15 Biotech Stocks That Hit Year Highs Over The Last Week, Including Sarepta, Axsome Investor's Business Daily
Aug-29-22 10:23AM	3 Biotech Stocks You Can Buy and Hold for the Next Decade Motley Fool
Aug-25-22 06:08AM	Trade Alert: Michael Chambers At Sarepta Therapeutics, Inc. (NASDAQ:SRPT), Has Just Spent US$5.0m Buying 61% More Shares Simply Wall St.
Aug-17-22 06:43PM	Did Sarepta Therapeutics Just Unveil a Breakthrough? TheStreet.com
Aug-15-22 10:44AM	Billionaire Ray Dalio Loads Up on These 3 Strong Buy Stocks TipRanks
Aug-12-22 03:45PM	These Four Biotech Stocks Sparkle In IBD 50 Investor's Business Daily
Aug-08-22 02:09PM	Sarepta In-Licenses Next-Gen AAV Tech Covering Five Indications Benzinga +5.14%
08:30AM	Sarepta Therapeutics Announces Progress on the MyoAAV Program and Exclusive Licensing Agreement with The Broad Institute for MyoAAV Next-generation Capsids for Rare Genetic Diseases GlobeNewswire
Aug-03-22 02:20PM	Sarepta's Duchenne Gene Therapy Update Gets Bullish Stance From Analysts Benzinga
12:44PM	Sarepta (SRPT) Q2 Earnings Miss, DMD Drugs' Sales Robust Zacks
Aug-02-22 11:30PM	Sarepta Therapeutics (SRPT) Q2 2022 Earnings Call Transcript Motley Fool
05:25PM	Sarepta Therapeutics (SRPT) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:05PM	Sarepta Therapeutics Announces Second Quarter 2022 Financial Results and Recent Corporate Developments GlobeNewswire

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; and AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program that is under Phase 1/2a clinical trial; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Selecta Biosciences; Hansa Biopharma; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BEHRENS M KATHLEEN	Director	Dec 19	Option Exercise	34.92	20,000	698,400	158,470	Dec 21 09:05 AM
Mayo Stephen	Director	Nov 17	Sale	109.92	858	94,311	6,387	Nov 21 08:00 PM
Chambers Michael Andrew	Director	Sep 14	Buy	104.43	57,100	5,963,124	108,178	Sep 15 08:00 AM
Chambers Michael Andrew	Director	Aug 19	Buy	108.28	46,170	4,999,230	51,078	Aug 22 08:30 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience